Paper Details

  1. Home
  2. Paper Details

Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Author: BarinF, ChironJ P, CoursagetP, DenisF, GoudeauA, MarI D, MaupasP, PerrinJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Hepatitis B vaccine was effective in preventing HBsAg carrier state in Senegalese children, with 94.5% of seronegative recipients developing an anti-HBs response. No adverse effects were reported.
Paper Details　
Original Abstract of the Article :
Three doses of inactivated hepatitis B vaccine were given at one-month intervals to Senegalese children aged less than two years. A control group received diphtheria/tetanus/polio vaccine. Of those HB vaccine recipients who were seronegative before immunisation, 94.5% had a specific anti-HBs respons...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(81)91908-5

データ提供：米国国立医学図書館（NLM）

Hepatitis B Vaccination: A Shield Against Early Carrier State

The fight against infectious diseases, like a journey through a desert, requires vigilance and proactive measures. This study examines the effectiveness of hepatitis B vaccination in preventing the early carrier state in children, a crucial step in safeguarding their health. The authors conducted a controlled trial in an endemic area, Senegal, where the disease is prevalent. They found that the vaccine effectively reduced the incidence of the HBsAg carrier state, offering a potent tool for disease prevention. This research, like a desert oasis, provides a valuable resource for public health efforts.

A Significant Reduction in HBsAg Carrier State

The study demonstrates a remarkable 85% reduction in the incidence of the HBsAg carrier state in susceptible children after twelve months. This significant reduction, like a cool breeze in the desert, offers a promising prospect for preventing the spread of this debilitating disease. The authors highlight the importance of proactive vaccination programs in protecting vulnerable populations.

A Vital Tool for Public Health

This study highlights the critical role of vaccination in preventing the spread of hepatitis B. The findings, like a well-mapped oasis, provide valuable guidance for public health initiatives aimed at controlling this infectious disease. The research underscores the importance of timely and effective vaccination programs in protecting communities from the devastating impact of this viral infection.

Dr.Camel's Conclusion

This study provides compelling evidence for the effectiveness of hepatitis B vaccination in preventing the early carrier state in children. The findings highlight the importance of timely and universal vaccination programs in protecting vulnerable populations. The research serves as a roadmap for public health initiatives, guiding us toward a healthier future.

Date :
  1. Date Completed 1981-04-21
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

6109938

DOI: Digital Object Identifier

10.1016/s0140-6736(81)91908-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.